These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34773309)

  • 21. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
    Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
    Front Immunol; 2022; 13():832263. PubMed ID: 35371054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
    Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
    Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
    FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
    Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
    Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis.
    Xiang Z; Li J; Song S; Wang J; Cai W; Hu W; Ji J; Zhu Z; Zang L; Yan R; Yu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):314. PubMed ID: 31315643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
    Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
    Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDO Targeting in Sarcoma: Biological and Clinical Implications.
    Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
    Front Immunol; 2020; 11():274. PubMed ID: 32194552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amino Acid Metabolism-Regulated Nanomedicine for Enhanced Tumor Immunotherapy through Synergistic Regulation of Immune Microenvironment.
    Duan X; Zhao Y; Hu H; Wang X; Yan J; Li S; Zhang Y; Jiao J; Zhang G
    Biomater Res; 2024; 28():0048. PubMed ID: 38966855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
    Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
    Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
    Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
    Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
    Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
    Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tryptophan metabolism in cancers and therapeutic implications.
    Liu XH; Zhai XY
    Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
    Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
    J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased effect of two-fraction radiotherapy in conjunction with IDO1 inhibition in experimental glioblastoma.
    Ahlstedt J; Konradsson E; Ceberg C; Redebrandt HN
    PLoS One; 2020; 15(5):e0233617. PubMed ID: 32469935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
    Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
    PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.
    Trézéguet V; Fatrouni H; Merched AJ
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.